Filing Flows › 8-K events › Cognition Therapeutics
Cognition Therapeutics: results of operations
Form 8-K filed Nov 5, 2026 · items 2.02, 3.01
Delisting noticesCognition Therapeutics Reports Financial Results for the Third Quarter 2026
What the filing says
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 - Management conference call at 8:30 a.m.
Read the filing on SEC EDGAR →
What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 3.01: 0.0% next session across 492. Every item ranked →
What this kind of filing means
Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.
Other recent delisting notices
- Barfresh Food Group Nov 6, 2026
- Fifth Era Acquisition Corp I Nov 6, 2026
- Tempest Therapeutics Nov 6, 2026
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- Knightscope Nov 6, 2026
- Curis Nov 6, 2026
- Intrusion Nov 5, 2026
- Karyopharm Therapeutics Nov 5, 2026
- Cayson Acquisition Nov 4, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.